Telemus Capital’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | $2.93M | Sell |
26,876
-1,139
| -4% | -$118K | 0.24% | 85 |
|
|
2023
Q3 | $2.88M | Sell |
28,015
-1,851
| -6% | -$200K | 0.27% | 80 |
|
|
2023
Q2 | $3.45M | Buy |
29,866
+135
| +0.5% | +$15.3K | 0.29% | 80 |
|
|
2023
Q1 | $3.16M | Buy |
29,731
+801
| +3% | +$86.5K | 0.28% | 82 |
|
|
2022
Q4 | $3.32M | Buy |
28,930
+11,547
| +66% | +$1.18M | 0.3% | 81 |
|
|
2022
Q3 | $1.5M | Buy |
17,383
+270
| +2% | +$24.1K | 0.15% | 124 |
|
|
2022
Q2 | $1.56M | Sell |
17,113
-1,615
| -9% | -$143K | 0.15% | 125 |
|
|
2022
Q1 | $1.54M | Sell |
18,728
-261
| -1% | -$20.6K | 0.13% | 138 |
|
|
2021
Q4 | $1.46M | Sell |
18,989
-637
| -3% | -$50.7K | 0.12% | 148 |
|
|
2021
Q3 | $1.47M | Buy |
19,626
+2,536
| +15% | +$193K | 0.12% | 141 |
|
|
2021
Q2 | $1.33M | Sell |
17,090
-25,775
| -60% | -$1.92M | 0.1% | 150 |
|
|
2021
Q1 | $3.15M | Buy |
42,865
+177
| +0.4% | +$13.1K | 0.22% | 93 |
|
|
2020
Q4 | $3.33M | Buy |
42,688
+227
| +0.5% | +$17.4K | 0.25% | 81 |
|
|
2020
Q3 | $3.23M | Buy |
42,461
+68
| +0.2% | +$5.33K | 0.24% | 83 |
|
|
2020
Q2 | $3.1M | Sell |
42,393
-352
| -0.8% | -$26.5K | 0.25% | 83 |
|
|
2020
Q1 | $3.29M | Sell |
42,745
-6,003
| -12% | -$472K | 0.27% | 78 |
|
|
2019
Q4 | $4.23M | Buy |
48,748
+335
| +0.7% | +$27.5K | 0.33% | 76 |
|
|
2019
Q3 | $3.89M | Buy |
48,413
+320
| +0.7% | +$25.6K | 0.31% | 73 |
|
|
2019
Q2 | $3.81M | Sell |
48,093
-3,738
| -7% | -$286K | 0.34% | 70 |
|
|
2019
Q1 | $4.11M | Sell |
51,831
-23,211
| -31% | -$1.74M | 0.31% | 72 |
|
|
2018
Q4 | $5.47M | Buy |
75,042
+23,256
| +45% | +$1.64M | 0.44% | 53 |
|
|
2018
Q3 | $3.5M | Buy |
51,786
+2,340
| +5% | +$149K | 0.26% | 82 |
|
|
2018
Q2 | $2.86M | Sell |
49,446
-329
| -0.7% | -$18.6K | 0.22% | 94 |
|
|
2018
Q1 | $2.59M | Sell |
49,775
-788
| -2% | -$42.6K | 0.21% | 98 |
|
|
2017
Q4 | $2.71M | Buy |
50,563
+18,658
| +58% | +$1.03M | 0.21% | 95 |
|
|
2017
Q3 | $1.95M | Buy |
31,905
+2,708
| +9% | +$164K | 0.22% | 81 |
|
|
2017
Q2 | $1.79M | Buy |
29,197
+769
| +3% | +$46.8K | 0.18% | 96 |
|
|
2017
Q1 | $1.72M | Buy |
28,428
+2,703
| +11% | +$164K | 0.18% | 91 |
|
|
2016
Q4 | $1.45M | Sell |
25,725
-9,598
| -27% | -$562K | 0.2% | 96 |
|
|
2016
Q3 | $2.1M | Sell |
35,323
-461
| -1% | -$27K | 0.24% | 85 |
|
|
2016
Q2 | $1.97M | Buy |
35,784
+762
| +2% | +$40.6K | 0.24% | 87 |
|
|
2016
Q1 | $1.77M | Buy |
+35,022
| New | +$1.72M | 0.29% | 80 |
|
|
2015
Q2 | – | Sell |
-3,722
| Closed | -$204K | – | 127 |
|
|
2015
Q1 | $204K | Sell |
3,722
-1,057
| -22% | -$59.9K | 0.05% | 129 |
|
|
2014
Q4 | $259K | Buy |
4,779
+10
| +0.2% | +$557 | 0.06% | 115 |
|
|
2014
Q3 | $270K | Sell |
4,769
-153
| -3% | -$8.59K | 0.07% | 105 |
|
|
2014
Q2 | $272K | Sell |
4,922
-724
| -13% | -$39.5K | 0.07% | 106 |
|
|
2014
Q1 | $306K | Buy |
5,646
+310
| +6% | +$16.1K | 0.08% | 95 |
|
|
2013
Q4 | $255K | Hold |
5,336
| – | – | 0.07% | 103 |
|
|
2013
Q3 | $242K | Buy |
+5,336
| New | +$244K | 0.07% | 126 |
|
Other funds holding MRK
Telemus Capital's MRK Position: Q4 2023 in Review
Telemus Capital reduced its Merck (MRK) stake by 4.1% in Q4 2023, selling an estimated $118K and leaving 26,876 shares worth $2.93M. The position accounts for 0.24% of the portfolio, ranked #85.
Telemus Capital first reported a position in MRK in Q3 2013 and has held it in 39 quarters since. The position peaked at $5.47M in Q4 2018. 3,434 funds tracked by Wall St. Rank hold MRK as of Q4 2023.
- Telemus Capital held 26,876 shares of Merck worth $2.93M as of Q4 2023.
- Telemus Capital sold 1,139 Merck shares in Q4 2023, an estimated $118K.
- Merck made up 0.24% of Telemus Capital's portfolio in Q4 2023, its #85 holding.
- Telemus Capital first reported a position in Merck in Q3 2013 and has held it in 39 quarters since.
- Telemus Capital's Merck position peaked at $5.47M in Q4 2018.
- 3,434 funds tracked by Wall St. Rank held Merck as of Q4 2023.
Based on Telemus Capital's 13F filing for Q4 2023, filed 1 Feb 2024.